Clinical Development
Clinical Pipeline
Nexavar® (sorafenib) tablets
Liver Cancer
Liver Cancer
SPACE – Locoregional therapy with TACE
STORM – Adjuvant
SEARCH – Nexavar w/ Tarceva®
Kidney Cancer
Advanced Kidney Cancer
SORCE/ASSURE – Adjuvant
Non-Small Cell Lung Cancer
MISSION – Third/Fourth-line, monotherapy
Thyroid Cancer
DECISION – Monotherapy
Breast Cancer
RESILIENCE – Capecitabine +/-
First/second-line, gemcitabine or capecitabine +/-
First-line, docetaxel or letrozole +/-
Ovarian Cancer
Maintenance
Colorectal Cancer
RESPECT – Combination
Carfilzomib
Multiple Myeloma
ASPIRE – Relapsed, lenalidomide/dexamethasone +/-
FOCUS – Relapsed/refractory, monotherapy
004 – Relapsed/refractory, single agent
005 – Relapsed and refractory, single agent
006 – Relapsed and/or refractory, single agent
Front-line – lenalidomide/dexamethasone +/-*
Solid Tumor
Monotherapy
Other
Cell Cycle Kinase Inhibitor
ONX 0912 (oral proteasome inhibitor)
ONX 0914 (immunoproteasome inhibitor)